Literature DB >> 33283131

Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression.

Noura J Choudhury1, Robert J Young2,3, Matthew Sellitti4, Alexandra Miller3,4, Alexander Drilon1,3.   

Abstract

Entities:  

Year:  2020        PMID： 33283131      PMCID： PMC7713518          DOI： 10.1200/PO.20.00271

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  23 in total

1.  Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.

Authors:  Takamasa Nakasuka; Eiki Ichihara; Go Makimoto; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  J Thorac Oncol       Date:  2019-08       Impact factor: 15.609

Review 2.  Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.

Authors:  Isabella Zhang; Nicholas G Zaorsky; Joshua D Palmer; Ranee Mehra; Bo Lu
Journal:  Lancet Oncol       Date:  2015-10       Impact factor: 41.316

Review 3.  Bevacizumab for malignant gliomas.

Authors:  Fabio M Iwamoto; Howard A Fine
Journal:  Arch Neurol       Date:  2010-03

4.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

5.  Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Kazuhiko Nakagawa; Edward B Garon; Takashi Seto; Makoto Nishio; Santiago Ponce Aix; Luis Paz-Ares; Chao-Hua Chiu; Keunchil Park; Silvia Novello; Ernest Nadal; Fumio Imamura; Kiyotaka Yoh; Jin-Yuan Shih; Kwok Hung Au; Denis Moro-Sibilot; Sotaro Enatsu; Annamaria Zimmermann; Bente Frimodt-Moller; Carla Visseren-Grul; Martin Reck
Journal:  Lancet Oncol       Date:  2019-10-04       Impact factor: 41.316

6.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

7.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors:  Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

8.  Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.

Authors:  Gonzalo Recondo; Laura Mezquita; Francesco Facchinetti; David Planchard; Anas Gazzah; Ludovic Bigot; Ahsan Z Rizvi; Rosa L Frias; Jean Paul Thiery; Jean-Yves Scoazec; Tony Sourisseau; Karen Howarth; Olivier Deas; Dariia Samofalova; Justine Galissant; Pauline Tesson; Floriane Braye; Charles Naltet; Pernelle Lavaud; Linda Mahjoubi; Aurélie Abou Lovergne; Gilles Vassal; Rastilav Bahleda; Antoine Hollebecque; Claudio Nicotra; Maud Ngo-Camus; Stefan Michiels; Ludovic Lacroix; Catherine Richon; Nathalie Auger; Thierry De Baere; Lambros Tselikas; Eric Solary; Eric Angevin; Alexander M Eggermont; Fabrice Andre; Christophe Massard; Ken A Olaussen; Jean-Charles Soria; Benjamin Besse; Luc Friboulet
Journal:  Clin Cancer Res       Date:  2019-10-04       Impact factor: 12.531

Review 9.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Authors:  Rakesh K Jain
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

10.  Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Authors:  Alice T Shaw; Enriqueta Felip; Todd M Bauer; Benjamin Besse; Alejandro Navarro; Sophie Postel-Vinay; Justin F Gainor; Melissa Johnson; Jorg Dietrich; Leonard P James; Jill S Clancy; Joseph Chen; Jean-François Martini; Antonello Abbattista; Benjamin J Solomon
Journal:  Lancet Oncol       Date:  2017-10-23       Impact factor: 41.316
View more
  2 in total

Review 1.  Anaplastic lymphoma kinase-special immunity and immunotherapy.

Authors:  Ye Guo; Hanfei Guo; Yongfei Zhang; Jiuwei Cui
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 2.  Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC).

Authors:  Aaron C Tan; Nick Pavlakis
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.